Interferon Patents (Class 424/85.4)
  • Patent number: 10364263
    Abstract: Compounds having the following formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, D, E and R1 are as defined herein, are provided. Methods comprising the use of such compounds for the treatment of neurological disorders, such as pantothenate kinase-associated neurodegeneration, and pharmaceutical compositions containing such compounds, and their use in the treatment of neurological disorders, also are provided.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: July 30, 2019
    Assignee: Retrophin, Inc.
    Inventors: Maria Beconi, Daniel Elbaum, Steven Harper, Savina Malancona
  • Patent number: 10350158
    Abstract: Methods of inhibiting the growth of cells or inducing cell death by contacting the cells with or introducing into the cells a composition including a 5? triphosphate, 2? fluoro-modified pyrimidine non-linear single stranded RNA at least 17 nucleotides long with a least 3 base pairings or a 5? triphosphate, 2? fluoro-modified double stranded RNA at least 17 base pairs long in an amount effective to inhibit cell growth, induce cell death or induce cytokine production by the cells. The methods also include administration of the compositions to a subject. The subject may have a proliferative disorder or infectious disease and administration of the compositions provided herein may treat the disorder or disease.
    Type: Grant
    Filed: January 2, 2018
    Date of Patent: July 16, 2019
    Assignee: Duke University
    Inventors: Jaewoo Lee, Johannes Urban, Bruce A. Sullenger
  • Patent number: 10259854
    Abstract: The field of the present invention relates to genetically engineered fusion molecules, methods of making said fusion molecules, and uses thereof in anti-tumor immunotherapies. More specifically, the present invention relates to fusion molecule constructs wherein a tumor associated antigen (TAA) antibody (Ab) serves as a targeting moiety to selectively deliver a cytokine to a tumor cell for purposes of killing or inhibiting the growth or proliferation of said tumor cell. In various embodiments, the engineered fusion molecules comprise a TAA Ab fused to an interferon-alpha (IFN-?) mutant molecule. The engineered Ab-IFN-? mutant fusion molecules of the present invention demonstrate improved therapeutic index and preserved or increased efficacy as compared to Ab-wildtype IFN-? fusion molecules, and/or demonstrate improved PK properties as compared to Ab-wildtype IFN-? fusion molecules.
    Type: Grant
    Filed: November 28, 2016
    Date of Patent: April 16, 2019
    Assignee: ImmunGene Inc
    Inventors: Iqbal Grewal, Sanjay Khare, Michael Gresser, Rashid Syed
  • Patent number: 10238666
    Abstract: This invention relates the use of cortisol blockers (e.g., glucocorticoid receptor [GR] antagonists) for the treating or preventing viral infections, treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.
    Type: Grant
    Filed: November 29, 2017
    Date of Patent: March 26, 2019
    Assignee: Pop Test Oncology LLC
    Inventors: Randice Lisa Altschul, Neil David Theise, Andreas J. Kesel, Myron Rapkin, Rebecca O'Brien, Anthony R. Arment
  • Patent number: 10174016
    Abstract: The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: December 7, 2015
    Date of Patent: January 8, 2019
    Assignee: BEYER AKTIENGESELLSCHAFT
    Inventors: Adam James Davenport, Nico Bräuer, Oliver Martin Fischer, Andrea Rotgeri, Antje Rottmann, Ioana Neagoe, Jens Nagel, Anne-Marie Godinho-Coelho, Jürgen Klar
  • Patent number: 10174290
    Abstract: A method for enhancing infectivity of HCMV virus particles is provided.
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: January 8, 2019
    Assignee: THE TRUSTEES OF PRINCETON UNIVERSITY
    Inventors: Thomas Shenk, Nicole Gudleski O'Regan, Todd M. Greco, Ileana M. Cristea
  • Patent number: 10150806
    Abstract: The invention features compositions and methods for site-specific modification of proteins by incorporation of an aldehyde tag. Enzymatic modification at a sulfatase motif of the aldehyde tag through action of a formylglycine generating enzyme (FGE) generates a formylglycine (FGly) residue. The aldehyde moiety of FGly residue can be exploited as a chemical handle for site-specific attachment of a moiety of interest to a polypeptide.
    Type: Grant
    Filed: August 16, 2016
    Date of Patent: December 11, 2018
    Assignee: The Regents of the University of California
    Inventors: Isaac S. Carrico, Brian L. Carlson, Peng Wu, Carolyn Ruth Bertozzi
  • Patent number: 10078086
    Abstract: Embodiments of the invention are directed to methods of diagnosing bacterial infection in a critically ill patient. The methods include obtaining a sample from the patient and determining the patient's level of IL-27 expression. Embodiments of the invention are also directed to methods that include determining both the patient's levels of IL-27 expression and PCT expression and using the combined result to provide a diagnosis of bacterial infection in a critically ill patient.
    Type: Grant
    Filed: August 30, 2013
    Date of Patent: September 18, 2018
    Assignee: Childrens Hospital Medical Center
    Inventor: Hector R. Wong
  • Patent number: 10046029
    Abstract: The present invention relates to a combination of at least two different substances, one of which activates the STAT1-signalling cascade and the other of which activates the TNFR1/CD95-signalling cascade in order to induce permanent growth arrest—i.e. senescence—in pre-malignant or malignant tumors or tumor cells. This induction of permanent growth arrest does not depend on cytotoxicity and does not primarily attempt to kill tumor cells, although this may occur. The induction serves to treat and/or prevent tumors by permanent growth arrest. The combination is used for therapeutic or preventative senescence induction in tumors, in which the STAT1- and TNFR1/CD95-signalling cascade can be activated and in which p16lnk4a is present. The invention transfers tumor cells and, contrary to many other therapies, the tumor stem cells, into permanent growth arrest.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: August 14, 2018
    Inventor: Martin Roecken
  • Patent number: 9956191
    Abstract: Disclosed are 5-nitrobenzoate derivatives of Formula I, and the preparation method therefor, wherein R is referred to hydrogen (H), unsubstituted, mono-substituted, di-substituted or tri-substituted benzoyl moiety. 5-Nitrobenzoare derivatives of Formula I do not affect the platelet aggregation, possesses the inhibitory activity related to the tumor cell-induced platelet aggregation (TCIPA), and further specifically inhibits podoplanin-induced platelet aggregation. Therefore, 5-nitrobenzoates of the invention are applicable in its therapeutic use as the novel therapeutic agent in preventing tumor metastasis.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: May 1, 2018
    Inventors: Ching-Ping Tseng, Pei-Wen Hsieh, Yao-Wen Chang
  • Patent number: 9944686
    Abstract: This invention provides a method for treating tumors in a subject, comprising administering to the subject an effective amount of a recombinant interferon, wherein the interferon has the amino acid sequence of SEQ ID NO:2 and is encoded by the nucleotide sequence SEQ ID NO:1, wherein the tumors are selected from the group consisting of skin cancer, basal cell carcinoma, liver cancer, thyroid cancer, rhinopharyngeal cancer, solid carcinoma, prostate cancer, esophageal cancer, pancreatic cancer, superficial bladder cancer, hemangioma, epidermoid carcinoma, cervical cancer, glioma, leucocythemia, acute leucocythemia, chronic leucocythemia, lymphadenoma, and polycythemia vera.
    Type: Grant
    Filed: September 5, 2013
    Date of Patent: April 17, 2018
    Assignee: SUPERLAB FAR EAST LIMITED
    Inventor: Guangwen Wei
  • Patent number: 9868727
    Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: January 16, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Weiguo Liu, Scott D. Edmondson, Zhuyan Guo, Sung-Sau So, Anthony K. Ogawa, Rongze Kuang, Heping Wu, Amjad Ali, Ying-Duo Gao, Yu Jiang, Chunsing Li, Tingting Yu
  • Patent number: 9861574
    Abstract: Methods of inhibiting the growth of cells or inducing cell death by contacting the cells with or introducing into the cells a composition including a 5? triphosphate, 2? fluoro-modified pyrimidine non-linear single stranded RNA at least 17 nucleotides long with a least 3 base pairings or a 5? triphosphate, 2? fluoro-modified double stranded RNA at least 17 base pairs long in an amount effective to inhibit cell growth, induce cell death or induce cytokine production by the cells. The methods also include administration of the compositions to a subject. The subject may have a proliferative disorder or infectious disease and administration of the compositions provided herein may treat the disorder or disease.
    Type: Grant
    Filed: April 9, 2014
    Date of Patent: January 9, 2018
    Assignee: Duke University
    Inventors: Jaewoo Lee, Johannes Urban, Bruce A. Sullenger
  • Patent number: 9827213
    Abstract: Provided are an astragalus membranaceus fermentation product and a method of producing the astragalus membranaceus fermentation product, in which a lactic acid bacteria starter or a yeast starter proliferated and cultured in a medium is inoculated into a mixture, in which astragalus membranaceus, sugar, and water are mixed, to be fermented, and then a pH of a fermentation material obtained by fermenting is measured, and the fermentation material having a pH within a predetermined range is filtered and dried to obtain the astragalus membranaceus fermentation product.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: November 28, 2017
    Assignee: COSISBIO CO., LTD.
    Inventors: Terry Cho Hyun, Sang-hurn Park, Dong-goo Kim, Ji-young Shin
  • Patent number: 9820972
    Abstract: Provided are compounds antiviral compounds represented by formula Ia and Ib: that are highly potent as HCV NS5A inhibitors, where the structural variables are as defined herein. These compounds are useful in, for example, inhibiting Hepatitis C virus and treating Hepatitis C virus infections.
    Type: Grant
    Filed: January 20, 2016
    Date of Patent: November 21, 2017
    Assignee: AB PHARMA LTD.
    Inventor: Zheng-Yun James Zhan
  • Patent number: 9783589
    Abstract: The field of the present invention relates to genetically engineered fusion molecules, methods of making said fusion molecules, and uses thereof for treatment of autoimmune diseases. More specifically, the present invention provides novel genetically engineered fusion molecules comprising an interferon (IFN) molecule attached to an antibody (Ab) which targets an antigen which is differentially expressed or up-regulated on activated T cells as compared to resting T cells, wherein the fusion molecule when contacted to an activated T cell results in induced apoptosis and programmed cell death or impairment of functions of said activated T cell.
    Type: Grant
    Filed: August 13, 2013
    Date of Patent: October 10, 2017
    Assignee: IMMUNGENE INC
    Inventors: Iqbal Grewal, Sanjay Khare, Michael Gresser
  • Patent number: 9763923
    Abstract: Provided is a method of reducing senescence in a cell or subject, or treating or preventing a symptom or disease associated therewith, by administering a BRAF inhibitor to the cell or subject.
    Type: Grant
    Filed: May 2, 2016
    Date of Patent: September 19, 2017
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Jungwon Keum, Joontae Park, Chulwon Jung, Sangchul Park, Youngsam Lee
  • Patent number: 9718782
    Abstract: The present invention is directed to benzyl urea compounds of formula (I) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence may be useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor Trk-A, Trk-B and/or Trk-C.
    Type: Grant
    Filed: September 17, 2014
    Date of Patent: August 1, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Andrew J. Cooke, Craig A. Stump, Xu-Fang Zhang, Chun Sing Li, Qinghua Mao
  • Patent number: 9707215
    Abstract: The present invention provides, among other things, compounds represented by the general Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, R2, and R3 are as defined in classes and subclasses herein and compositions (e.g., pharmaceutical compositions) comprising such compounds, which compounds are useful as inhibitors of hepatitis C virus polymerase, and thus are useful, for example, as medicaments for the treatment of HCV infection.
    Type: Grant
    Filed: June 20, 2013
    Date of Patent: July 18, 2017
    Assignee: COCRYSTAL, DISCOVERY, INC.
    Inventors: Sam Lee, Wang Shen, Xiaoling Zheng, Irina C. Jacobson
  • Patent number: 9695224
    Abstract: The present invention provides stably crosslinked insulinotropic polypeptides having superior and unexpected benefits in the treatment of conditions involving abnormal glucose homeostasis, e.g., type 2 diabetes and conditions relating to type 2 diabetes. Such benefits include, but are not limited to, extended polypeptide half-life, enhanced alpha-helicity, improved thermal stability and protease resistance, increased functional activity and pharmacologic properties, improved bioavailability when administered by any route, and improved bioavailability and gastrointestinal absorption when delivered orally, as compared to the corresponding unmodified polypeptides. The invention also provides compositions for administering the polypeptides of the invention, as well as methods for preparing and evaluating the polypeptides of the invention.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: July 4, 2017
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Loren D. Walensky, Gregory Bird
  • Patent number: 9682100
    Abstract: Antiviral cationic polyamines were prepared by modifying polyethylenimines with N-acylating agents that introduce a side chain comprising one or more carbons and at least one alcohol hydroxy group. The cationic polyamines can have a linear or branched polyethylenimine backbone structure. Preferably, the cationic polyamines comprise pendant monosaccharide groups, which can be introduced via a cyclic carbonate comprising a pendant protected monosaccharide (e.g., mannose) group. The cationic polyamines can be active and selective against a broad spectrum of viruses at low concentrations, and are generally non-toxic.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: June 20, 2017
    Assignees: International Business Machines Corporation, Agency For Science, Technology And Research, National University of Singapore
    Inventors: James L. Hedrick, Ichiyama Koji, Naoki Yamamoto, Chuan Yang, Yi Yan Yang
  • Patent number: 9623022
    Abstract: Inhibitors of HCV replication of formula (I) and the N-oxides, salts, and stereoisomers, wherein each dashed line represents an optional double bond; X is N, CH and where X bears a double bond it is C; R1 is —OR7, —NH—SO2R8; R2 is hydrogen, and where X is C or CH, R2 may also be C1-6alkyl; R3 is hydrogen, C1-6alkyl, C1-6alkoxyC1-6alkyl, C3-7cycloalkyl; R4 is aryl or Het; n is 3, 4, 5, or 6; R5 is halo, C1-6alkyl, hydroxy, C1-6alkoxy, phenyl, or Het; R6 is C1-6alkoxy, or dimethylamino; R7 is hydrogen; aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; R8 is aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; aryl is phenyl optionally substituted with one, two or three substituents; Het is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1 to 4 heteroatoms selected from nitrog
    Type: Grant
    Filed: April 25, 2016
    Date of Patent: April 18, 2017
    Assignees: Janssen Sciences Ireland UC, Medivir AB
    Inventors: Kenneth Alan Simmen, Herman Augustinus De Kock, Pierre Jean-Marie Bernard Raboisson, Lili Hu, Abdellah Tahri, Dominique Louis Nestor Ghislain Surleraux, Karl Magnus Nilsson, Bengt Bertil Samuelsson, Åsa Annica Kristina Rosenquist, Vladimir Ivanov, Mikael Pelcman, Anna Karin Belfrage, Per-Ola Mikael Johansson, Sandrine Marie Helene Vendeville
  • Patent number: 9616058
    Abstract: The present invention relates to the use of potent selective LSD inhibitors and LSD/MAO-B inhibitors for treating or preventing viral infections. Furthermore, the present invention relates to the new use of cyclopropylamine acetamide derivatives or cyclopropylamine derivatives, as defined herein, for treating or preventing viral infection and treating or preventing reactivation of a virus after latency.
    Type: Grant
    Filed: February 24, 2011
    Date of Patent: April 11, 2017
    Assignee: Oryzon Genomics, S.A.
    Inventors: Julio Cesar Castro Palomino Laria, Alberto Ortega Muñoz, Nathalie Guibourt, Jonathan Alleman Baker
  • Patent number: 9598433
    Abstract: Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: March 21, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Li-Qiang Sun, Eric P. Gillis, Eric Mull, Michael S. Bowsher, Qian Zhao, Paul Michael Scola
  • Patent number: 9593108
    Abstract: The present invention is directed to compounds and forms and pharmaceutical compositions thereof useful for treating a viral infection, or for affecting viral activity by modulating viral replication.
    Type: Grant
    Filed: April 5, 2010
    Date of Patent: March 14, 2017
    Assignee: PTC Therapeutics, Inc.
    Inventors: Malcolm Maccoss, F. George Njoroge, Amin Nomeir, Guangming Chen, Gary Mitchell Karp, William Jospeh Lennox, Chunshi Li, Christie Morrill, Steven D. Paget, Hongyu Ren, Nanjing Zhang, Xiaoyan Zhang
  • Patent number: 9579391
    Abstract: Conjugates which comprise a drug and a ligand which includes a first saccharide; wherein the conjugate is characterized in that, when the conjugate is administered to a mammal, at least one pharmacokinetic or pharmacodynamic property of the conjugate is sensitive to serum concentration of a second saccharide. Exemplary conjugates and sustained release formulations are provided in addition to methods of use and preparation.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: February 28, 2017
    Assignee: SmartCells, Inc.
    Inventors: Todd C. Zion, Thomas M. Lancaster
  • Patent number: 9573978
    Abstract: The present invention relates to a compound of the formula (I), (II), (III), (IV), (V), or (VI) or pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same, a method for treating or preventing a viral infection using the same.
    Type: Grant
    Filed: August 12, 2011
    Date of Patent: February 21, 2017
    Assignee: S&T GLOBAL, INC.
    Inventors: Zhuang Su, Zhengyu Long, Zhennian Huang, Suizhou Yang
  • Patent number: 9534057
    Abstract: The field of the present invention relates to genetically engineered fusion molecules, methods of making said fusion molecules, and uses thereof in anti-tumor immunotherapies. More specifically, the present invention relates to fusion molecule constructs wherein a tumor associated antigen (TAA) antibody (Ab) serves as a targeting moiety to selectively deliver a cytokine to a tumor cell for purposes of killing or inhibiting the growth or proliferation of said tumor cell. In various embodiments, the engineered fusion molecules comprise a TAA Ab fused to an interferon-alpha (IFN-?) mutant molecule. The engineered Ab-IFN-? mutant fusion molecules of the present invention demonstrate improved therapeutic index and preserved or increased efficacy as compared to Ab-wildtype IFN-? fusion molecules, and/or demonstrate improved PK properties as compared to Ab-wildtype IFN-? fusion molecules.
    Type: Grant
    Filed: February 2, 2015
    Date of Patent: January 3, 2017
    Assignee: IMMUNGENE INC
    Inventors: Iqbal Grewal, Sanjay Khare, Michael Gresser, Rashid Syed
  • Patent number: 9511056
    Abstract: The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: May 16, 2014
    Date of Patent: December 6, 2016
    Assignee: Gilead Pharmasset LLC
    Inventors: Elizabeth M. Bacon, Eda Canales, Aesop Cho, Jeromy J. Cottell, Manoj C. Desai, Michael Graupe, Hongyan Guo, Randall L. Halcomb, Darryl Kato, Choung U. Kim, Thorsten A. Kirschberg, Evan S. Krygowski, Scott E. Lazerwith, John O. Link, Hongtao Liu, Qi Liu, Richard L. Mackman, Michael L. Mitchell, Jay P. Parrish, Hyung-Jung Pyun, Joseph H. Saugier, Scott D. Schroeder, Jianyu Sun, James G. Taylor, James D. Trenkle, Winston C. Tse, Randall W. Vivian, William J. Watkins, Lianhong Xu
  • Patent number: 9511059
    Abstract: The present invention discloses compounds of Formula I: wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection.
    Type: Grant
    Filed: August 17, 2015
    Date of Patent: December 6, 2016
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Joseph Anthony Bilotta, Zhi Chen, Qingjie Ding, Shawn David Erickson, Eric Mertz, Robert James Weikert
  • Patent number: 9486502
    Abstract: Particular aspects of the invention provide methods for decreasing the amount of fluid present in the subretinal space of the eye by administering interferon gamma to the basolateral side of the retinal pigment epithelium. Adverse ocular conditions associated with the accumulation of fluid in the subretinal space can be treated by administering an amount of interferon gamma to the basolateral side of the retinal pigment epithelium effective to remove excess fluid from the subretinal space.
    Type: Grant
    Filed: April 14, 2014
    Date of Patent: November 8, 2016
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Rong Li, Sheldon S. Miller, Arvydas Maminishkis
  • Patent number: 9453051
    Abstract: The present invention relates to novel cyclosporin derivatives that do not cross the cellular membrane. The compounds according to the invention are used in medicine, more particularly in the treatment/diagnosis of acute and chronic inflammatory diseases, viral infections, cancer, degenerative muscle diseases, neurodegenerative diseases and damage that is associated with calcium homeostasis impairment. The novel cyclosporin derivatives additionally have no immunosuppressive effect.
    Type: Grant
    Filed: August 29, 2012
    Date of Patent: September 27, 2016
    Assignees: Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V., Lead Discovery Center GmbH
    Inventors: Gunter Fischer, Miroslav Malesevic, Frank Erdmann, Jan Kuhling, Michael Bukrinsky, Stephanie Constant, Gerd Ruhter, Peter Nussbaumer, Klaus Dinkel
  • Patent number: 9428491
    Abstract: The present invention relates to novel antiviral active 5-{4-[1H-imidazol-5-ylaryl(or hetaryl)]-buta-1,3-diynyl}-1H-imidazoles of the general formula 1 and pharmaceutically acceptable salt thereof, pharmaceutical composition, antiviral medicament, therapeutic kit for prophylaxis and treatment of hepatisis C virus diseases, and method for prophylaxis and treatment of hepatisis C. wherein: R1 and R2—represent optionally identical radicals selected from 2.1 and 2.2, where an asterisk (*) denotes the position of attachment to the imidazole fragment, (S) and (R) are types of chiral centers; R3 is isopropyl or phenyl radicals; Ar an aromatic or heteroaromatic diradical.
    Type: Grant
    Filed: November 28, 2011
    Date of Patent: August 30, 2016
    Inventors: Alexandre Vasilievich Ivachtchenko, Vadim Vasilievich Bichko, Oleg Dmitrievich Mitkin
  • Patent number: 9402831
    Abstract: A pharmaceutical combination comprising a BRAF inhibitor, and an Hsp90 inhibitor according to the following formulae (I): or a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables are defined therein. Also provided is a method for treating a proliferative disorder in a subject in need thereof, using the pharmaceutical combination described herein.
    Type: Grant
    Filed: November 14, 2012
    Date of Patent: August 2, 2016
    Assignee: Synta Pharmaceutical Corp.
    Inventors: David Proia, Jaime Acquaviva
  • Patent number: 9334291
    Abstract: Provided are compounds antiviral compounds represented by formula Ia and Ib: that are highly potent as HCV NS5A inhibitors, where the structural variables are as defined herein. These compounds are useful in, for example, inhibiting Hepatitis C virus and treating Hepatitis C virus infections.
    Type: Grant
    Filed: June 6, 2014
    Date of Patent: May 10, 2016
    Assignee: AB PHARMA LTD.
    Inventor: Zheng-Yun James Zhan
  • Patent number: 9296778
    Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.
    Type: Grant
    Filed: May 21, 2013
    Date of Patent: March 29, 2016
    Assignees: Idenix Pharmaceuticals, Inc., Centre National De La Recherche Scientifique, Universite Montpellier 2 Sciences Et Techniques
    Inventors: Christophe Claude Parsy, Francois-Rene Alexandre, Cyril B. Dousson, David Dukhan, Gilles Gosselin, Houcine Rahali, Dominique Surleraux
  • Patent number: 9283280
    Abstract: The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject, as well as compositions and methods for providing migraine pain relief. The compositions include at least one alkyl glycoside and at least one therapeutic agent, such as a 5-HT receptor agonist, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms.
    Type: Grant
    Filed: May 13, 2013
    Date of Patent: March 15, 2016
    Assignee: Aegis Therapeutics, LLC
    Inventor: Edward T. Maggio
  • Patent number: 9200024
    Abstract: A methodology for polymer grafting by a polysaccharide synthase allows the creation of a variety of glycosaminoglycan oligosaccharides that have a natural, chimeric, hybrid and/or unnatural sugar structure and/or a targeted size (i.e., substantially monodisperse in size).
    Type: Grant
    Filed: December 14, 2011
    Date of Patent: December 1, 2015
    Assignee: The Board of Regents of the University of Oklahoma
    Inventors: Paul L. DeAngelis, Alison Sismey-Ragatz
  • Patent number: 9198907
    Abstract: The present invention is directed to a combination product for treating or ameliorating hepatitis C virus (HCV) infection or disorders or symptoms associated therewith in a subject in need thereof comprising, a HCV inhibitor and one or more therapeutic agents selected from either or both a HCV protease inhibitor and one or more different therapeutic agents administered in combination in an effective amount to the subject.
    Type: Grant
    Filed: April 5, 2010
    Date of Patent: December 1, 2015
    Assignee: PTC Therapeutics, Inc.
    Inventors: Frederick C. Lahser, Zhengxian Gu
  • Patent number: 9193740
    Abstract: The present invention discloses compounds of formula Ia or Ib or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: October 19, 2010
    Date of Patent: November 24, 2015
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Yonghua Gai, Yat Sun Or, Guoqiang Wang
  • Patent number: 9139570
    Abstract: Amorphous and crystalline solid forms of the anti-HCV compound (1-{3-[6-(9,9-difluoro-7-{2-[5-(2-methoxycarbonylamino-3-methyl-butyryl)-5-aza-spiro[2.4]hept-6-yl]-3H-imidazol-4-yl}-9H-fluoren-2-yl)-1H-benzoimidazol-2-yl]-2-aza-bicyclo[2.2.1]heptane-2-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the amorphous and crystalline forms.
    Type: Grant
    Filed: January 20, 2015
    Date of Patent: September 22, 2015
    Assignee: GILEAD PHARMASSET LLC
    Inventors: Erik Mogalian, Robert William Scott, Bing Shi, Fang Wang
  • Patent number: 9133170
    Abstract: The present invention provides compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
    Type: Grant
    Filed: December 13, 2012
    Date of Patent: September 15, 2015
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: John A. Brinkman, Ramakanth Sarabu, Sung-Sau So
  • Patent number: 9101539
    Abstract: Methods are provided for the engineering of inhalable dry powder pharmaceutical formulations with desired pharmacokinetic profiles and parameters. Compositions with improved pharmacokinetics are disclosed.
    Type: Grant
    Filed: May 14, 2010
    Date of Patent: August 11, 2015
    Assignee: SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.
    Inventors: Ryoichi Nagata, Shunji Haruta
  • Patent number: 9045463
    Abstract: Inhibitors of HCV replication of formula I including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein R and R* have the meaning defined in the claims. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HCV inhibitors, in the treatment or prophylaxis of HCV.
    Type: Grant
    Filed: August 6, 2010
    Date of Patent: June 2, 2015
    Assignee: Janssen R&D Ireland
    Inventors: David McGowan, Samuel Dominique Demin, Stefaan Julien Last, Koen Vandyck, Pierre Jean-Marie Bernard Raboisson
  • Publication number: 20150139944
    Abstract: Provided is a separatome-based recombinant peptide, polypeptide, and protein expression and purification platform based on the juxtaposition of the binding properties of host cell genomic peptides, polypeptides, and proteins with the characteristics and location of the corresponding genes on the host cell chromosome, such as that of E. coli, yeast, Bacillus subtilis or other prokaryotes, insect cells, mammalian cells, etc. This platform quantitatively describes and identifies priority deletions, modifications, or inhibitions of certain gene products to increase chromatographic separation efficiency, defined as an increase in column capacity, column selectivity, or both, with emphasis on the former. Moreover, the platform provides a computerized knowledge tool that, given separatome data and a target recombinant peptide, polypeptide, or protein, intuitively suggests strategies leading to efficient product purification.
    Type: Application
    Filed: October 23, 2014
    Publication date: May 21, 2015
    Inventors: Ellen M. Brune, Robert R. Beitle, Mohammad M. Ataai, Patrick R. Bartlow, Ralph L. Henry
  • Publication number: 20150139946
    Abstract: Provided is a method for monitoring a gene mutation associated with a cancer in a patient over time. Also provided is a method of selecting and/or applying treatment or therapy for a subject.
    Type: Application
    Filed: October 19, 2014
    Publication date: May 21, 2015
    Inventors: Mark G. Erlander, Karena Kosco, Cecile Rose Vibat
  • Patent number: 9034310
    Abstract: A method for pharmacological treatment of cancers and other diseases is presented which includes the novel combination of a statin (Hmg-CoA reductase inhibitor, such as lovastatin, simvastatin, atorvastatin, cerivastatin, fluvastatin, pravastatin, or newer agents), with an interferon (such as interferon alfa-2b or others) and also including concurrent administration of selenium and calcium. The method disclosed in this invention is useful because it can prove more effective than previously known therapies for certain diseases and because its use may be more tolerable, less disfiguring, and less expensive than other methods. The method here disclosed can be readily reproduced by any person skilled in the art of treating disease.
    Type: Grant
    Filed: February 20, 2003
    Date of Patent: May 19, 2015
    Inventor: Stephen B. Cantrell
  • Publication number: 20150132260
    Abstract: The present invention relates to the use of the measure of anelloviral load for the determination of immunosuppression. More precisely, the present invention provides a method for characterizing the immunosuppressed or non-immunosuppressed status of a subject, comprising the steps of determining the anelloviral load from a biological sample of the said subject, and determining from the said comparison the immunosuppressed or non-immunosuppressed status. The determination of the immunosuppressed status of the subject can then be used to design or adapt a therapeutic treatment.
    Type: Application
    Filed: April 19, 2013
    Publication date: May 14, 2015
    Inventors: Marc Eloit, Justine Cheval, Charles Hebert, Marc Lecuit
  • Publication number: 20150132258
    Abstract: Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
    Type: Application
    Filed: November 14, 2014
    Publication date: May 14, 2015
    Inventor: George D. Hartman
  • Publication number: 20150125422
    Abstract: Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Application
    Filed: January 8, 2015
    Publication date: May 7, 2015
    Inventors: Sheldon Hiebert, Ramkumar Rajamani, Li-Qiang Sun, Eric Mull, Eric P. Gillis, Michael S. Bowsher, Qian Zhao, Nicholas A. Meanwell, Kishore V. Renduchintala, Kandhasamy Sarkunam, Pulicharla Nagalakshmi, P.V.K. Suresh Babu, Paul Michael Scola